Apac Cancer Biological Therapy Market Size was valued at USD 114.08 Billion in 2023. The Global Apac Cancer Biological Therapy industry is projected to grow from USD 124.30 Billion in 2024 to USD 246.95 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.23% during the forecast period (2024 - 2032).
Cancer is the leading and the second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and others.
Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor, such therapies known as; cancer targeted therapies.
The major driving factors for Asia Pacific cancer biological therapy market are increasing cancer survival rates, growing demand for advanced therapies such as biological therapy, growth of cancer healthcare facilities in emerging countries, etc. Additionally, less number of side effects associated with biological therapy as compared to conventional treatment methods is the critical growth factor. Conventional cancer treatment methods like chemotherapy, radiotherapy give effective result, but along with that these methods also show its counter effects on body.
The side effects may include, loss of hair, weakened immune system, and such others depending upon the type, and phase of cancer. Biological therapies help to reduce the level of side effects as compared to other treatment methods. Biological therapies are giving the same amount of success rate for curing the cancer patient with 1st stage cancer approximately 27% to 35%. Owing to low level of side effects and high success rate of this therapy, the market is expected to grow rapidly. However, high cost of the treatment may restrain the market growth.
The leading market players in the Asia Pacific cancer biological therapy market include:
Asia Pacific cancer biological therapy market is segmented into types, phases, and end users.
On the basis of types the market is segmented into monoclonal antibodies, interferon, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines, and others. On the basis of phases, the market is segmented into phase I, phase II, and phase III.
On the basis of end users, the market is segmented into hospitals & clinics, cancer research centers, laboratories, and others.
China dominates the Asia Pacific cancer biological therapy market owing to increasing prevalence of cancer. Increasing adoption of smoking by people, rapid research & development and presence rapidly developing economy in this region fuel the growth of the market in Asia Pacific. Japan and Australia are other major contributor to the market growth in this region.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size 2023 | 114.08 (USD Billion) |
| Market Size 2024 | 124.30 (USD Billion) |
| Market Size 2032 | 246.95 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 9.23 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Geographies Covered | Asia Pacific |
| Key Vendors | Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Amgen Inc. (US), Bristol-Myers Squibb (US), Celgene (US), Eli Lilly and Company (US), EnGeneIC (Australia), Pfizer (US), Intas Pharmaceuticals Ltd. (India), and Sun Pharmaceutical Industries Ltd. (India) |
APAC Cancer Biological Therapy Market Highlights:
Frequently Asked Questions (FAQ) :
The projected CAGR of Asia Pacific Cancer Biological Therapy Market would 9.23% during the forecast period of 2024-2032.
The Asia Pacific Cancer Biological Therapy Market could be deterred by the high cost involved in the process.
The players are F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), Novartis AG (Switzerland), Amgen Inc. (US), Pfizer (US), Intas Pharmaceuticals Ltd. (India), Eli Lilly and Company (US), EnGeneIC (Australia), Celgene (US), and Sun Pharmaceutical Industries Ltd. (India).
Asia Pacific Cancer Biological Therapy Market segmented by types into interferon, monoclonal antibodies, cancer growth inhibitors, interleukins, colony-stimulating factors, gene therapy, cancer vaccines, targeted therapy, and others.
Asia Pacific Cancer Biological Therapy Market segmented by end users into laboratories, cancer research centers, hospitals & clinics, and others.
Asia Pacific cancer biological therapy market is expected to grow at a CAGR of 7.7% during the forecasted 2022-2030
$172.45 Billion
7.7%
Asia Pacific
2022-2030
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
